Louise Frederika Kooij Sells 32,612 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 32,612 shares of the company’s stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $31.80, for a total transaction of $1,037,061.60. Following the completion of the transaction, the chief accounting officer owned 24,353 shares in the company, valued at $774,425.40. This trade represents a 57.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Louise Frederika Kooij also recently made the following trade(s):

• On Tuesday, January 27th, Louise Frederika Kooij sold 39,816 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $32.62, for a total transaction of $1,298,797.92.
• On Monday, January 26th, Louise Frederika Kooij sold 34,400 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $32.78, for a total transaction of $1,127,632.00.
• On Friday, January 23rd, Louise Frederika Kooij sold 38,172 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.75, for a total transaction of $1,288,305.00.
• On Monday, January 5th, Louise Frederika Kooij sold 2,647 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.25, for a total value of $88,012.75.
• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.30, for a total value of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $36.21, for a total value of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.68, for a total value of $928,072.48.

NewAmsterdam Pharma Stock Performance

NAMS opened at $31.12 on Friday. NewAmsterdam Pharma Company N.V. has a 52-week low of $14.06 and a 52-week high of $42.00. The firm has a market cap of $3.53 billion, a P/E ratio of -15.18 and a beta of 0.07. The business’s fifty day moving average is $35.05 and its 200-day moving average is $31.31.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). The company had revenue of $0.35 million during the quarter, compared to analyst estimates of $4.54 million. NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. On average, research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on NAMS. Leerink Partners reiterated an “outperform” rating and set a $55.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. The Goldman Sachs Group upped their target price on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 2nd. Citigroup lifted their price target on NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Stifel Nicolaus boosted their price target on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $47.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NAMS. Arizona State Retirement System lifted its stake in shares of NewAmsterdam Pharma by 3.8% in the 3rd quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $377,000 after acquiring an additional 483 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in NewAmsterdam Pharma by 2.4% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 22,549 shares of the company’s stock worth $408,000 after purchasing an additional 521 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in NewAmsterdam Pharma by 5.3% in the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after purchasing an additional 544 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in NewAmsterdam Pharma by 18.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company’s stock valued at $79,000 after purchasing an additional 662 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in shares of NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after purchasing an additional 708 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.